Abstract: A dialyzer (15) includes a hollow fiber dialysis column (20), a liquid tubing section (12a), and a flow rate changing section (16a). The hollow fiber dialysis column (20) includes a hollow fiber membrane, a first flow channel that allows a dialysis target to flow internally of the hollow fiber membrane, and a second flow channel that allows an external liquid to flow externally of the hollow fiber membrane. The liquid tubing section (12a) tubes the dialysis target to an inlet (20a) of the first flow channel. The flow rate changing section (16a) is capable of changing a flow rate of the dialysis target at the dialysis target flowing out of an outlet (20b) of the first flow channel.

Abstract: A heart failure marker that is simple, and preferably usable by non-invasive test. A method for measuring heart failure risk, comprising: (A) measuring an angiotensinogen amount value of urine collected from a subject.

Abstract: Provided is an improved glucose-containing peritoneal dialysate, an ophthalmic composition, or an infusion that can suppress a blood glucose level increase even when used in a long-term treatment and can also suppress an infectious disease, by only addition. A D-glucose-containing osmotic pressure regulator includes D-allose and/or D-allulose as an additive for suppressing a blood glucose level increase by continuous absorption of glucose into the body and for suppressing an infectious disease. The osmotic pressure regulator is used as a mixture with a peritoneal dialysate, an ophthalmic composition, or an infusion. A peritoneal dialysis method for suppressing a blood glucose level increase by continuous absorption of glucose into the body through peritoneal dialysis and for suppressing an infectious disease uses a dialysate containing D-allose and/or D-allulose in an effective amount.

Abstract: Provided are a pulse wave signal analyzer and an analysis method capable of determining a state of atrial fibrillation. The analyzer comprises a pulse wave detection unit for non-invasively detecting a pulse wave signal according to heartbeat of a living body; a spectrum generation unit for generating a frequency spectrum by Fourier transforming signal detected by the pulse wave detection unit; and an atrial fibrillation detection unit for detecting a state of atrial fibrillation based on the frequency spectrum generated by the spectrum generation unit. The spectrum generation unit repeatedly performs Fourier transform of the pulse wave signal at a predetermined time frame while shifting the time frame in a range of 0.005 to 0.02 seconds. The analyzer further comprises a filter for filtering the signal detected by the pulse wave detection unit, and the spectrum generation unit generates the frequency spectrum from signal output from the filter.

Abstract: A dialyzer (15) includes a hollow fiber dialysis column (20), a liquid tubing section (12a), and a flow rate changing section (16a). The hollow fiber dialysis column (20) includes a hollow fiber membrane, a first flow channel that allows a dialysis target to flow internally of the hollow fiber membrane, and a second flow channel that allows an external liquid to flow externally of the hollow fiber membrane. The liquid tubing section (12a) tubes the dialysis target to an inlet (20a) of the first flow channel. The flow rate changing section (16a) is capable of changing a flow rate of the dialysis target at the dialysis target flowing out of an outlet (20b) of the first flow channel.

Abstract: A regeneration promoter for regenerating tissue with the use of somatic stem cells is provided. Also provided are a cell fusion promoter comprising ATP or its metabolite which is safely usable in vivo, a method of producing fused cells in the presence of ATP or its metabolite and a related pharmaceutical composition for regenerating or improving the function of a tissue or an organ in a subject suffering from dysfunction or hypofunction due to injury or denaturation.

Abstract: The present invention relates to a novel preventive and/or therapeutic drug for myocardial infarction. The present invention provides a preventive and/or therapeutic drug for myocardial infarction or myocardial ischemia-reperfusion injury, the drug containing a lipid membrane structure retaining adenosine.

Abstract: A pharmaceutical composition which comprises, as an active ingredient, a liposome encapsulating an immunosuppressant such as FK506, FTY720 and cyclosporin A is effective in the treatment of cardiovascular inflammatory diseases such as my ocardial infarction, myocarditis and vasculitis syndrome, allows the immunosuppressant at a low dose to produce stronger effects than those of the same dose of the immunosuppressant used alone, and causes fewer side effects.

Abstract: The present invention provides a regeneration promoter for regenerating tissue with the use of somatic stem cells. The invention also provides a cell fusion promoter comprising ATP or its metabolite which is safely usable in vivo, a method of producing fused cells in the presence of ATP or its metabolite and a related pharmaceutical composition for regenerating or improving the function of a tissue or an organ in a subject suffering from dysfunction or hypofunction due to injury or denaturation.

Abstract: A complex essentially comprising a protein having an action of binding to a membrane-bound HB-EGF to promote the uptake of the membrane-bound HB-EGF by cells, and a carrier.

Abstract: It is intended to provide a regeneration promoter for regenerating a tissue with the use of somatic stem cells. It is also intended to provide a cell fusion promoter safely usable in vivo. Namely, it is intended to provide a cell fusion promoter comprising ATP or its metabolite. A cell fusion promoter comprising ATP or its metabolite and a method of producing fused cells in the presence of ATP or its metabolite. A medicinal composition for regenerating or improving the function of a tissue or an organ, which suffers from dysfunction or hypofunction due to injury or denaturation, by using stem cells. This composition comprises ATP or its metabolite and a pharmaceutically acceptable carrier.

Abstract: The present invention provides a regeneration promoter for regenerating tissue with the use of somatic stem cells. The invention also provides a cell fusion promoter comprising ATP or its metabolite which is safely usable in vivo, a method of producing fused cells in the presence of ATP or its metabolite and a related pharmaceutical composition for regenerating or improving the function of a tissue or an organ in a subject suffering from dysfunction or hypofunction due to injury or denaturation.

Abstract: The present invention relates to a novel preventive and/or therapeutic drug for myocardial infarction. The present invention provides a preventive and/or therapeutic drug for myocardial infarction or myocardial ischemia-reperfusion injury, the drug containing a lipid membrane structure retaining adenosine.

Abstract: It is intended to provide a regeneration promoter for regenerating a tissue with the use of somatic stem cells. It is also intended to provide a cell fusion promoter safely usable in vivo. Namely, it is intended to provide a cell fusion promoter comprising ATP or its metabolite. A cell fusion promoter comprising ATP or its metabolite and a method of producing fused cells in the presence of ATP or its metabolite. A medicinal composition for regenerating or improving the function of a tissue or an organ, which suffers from dysfunction or hypofunction due to injury or denaturation, by using stem cells. This composition comprises ATP or its metabolite and a pharmaceutically acceptable carrier.